Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for chemotherapy-induced anorexia in breast or gastrointestinal cancer
IRCT20150609022632N2Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anorexia nervosa (AN), breast cancer and gastrointestinal cancer comparing Olanzapine with Placebo (2 arms). Primary endpoints: Change in appetite, Change in weight and 2 more. Started May 2025; status: completed.
02
Drugs
olanzapine
03
Conditions
anorexia nervosa (AN)breast cancergastrointestinal cancer
Beyond the preview
Go deeper on IRCT20150609022632N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150609022632N2.